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Abstract 
Background: A recent epidemiological study of esophageal cancer patients concluded statin 
use post-diagnosis was associated with large (38%) and significant reductions in cancer-
specific mortality. We investigated statin use and cancer-specific mortality in a large 
population-based cohort of esophageal cancer patients.   
 
Methods: Newly diagnosed (2009-2012) esophageal cancer patients were identified from the 
Scottish Cancer Registry and linked with the Prescribing Information System and Scotland 
Death Records (to January 2015).  Time-dependent Cox regression models were used to 
calculate hazard ratios (HR) for cancer-specific mortality and 95% confidence intervals (CIs) 
by post-diagnostic statin use (using a 6 month lag to reduce reverse causation) and to adjust 
these HRs for potential confounders.  
 
Results: 1,921 esophageal cancer patients were included in the main analysis, of whom 651 
(34%) used statins after diagnosis. There was little evidence of a reduction in esophageal 
cancer-specific mortality in statin users compared with non-users after diagnosis (adjusted 
HR=0.93, 95% CI, 0.81,1.07) and no dose response associations were seen. However, statin 
users compared with non-users in the year before diagnosis had a weak reduction in 
esophageal cancer-specific mortality (adjusted HR=0.88, 95% CI, 0.79,0.99).  
 
Conclusions: In this large population-based esophageal cancer cohort, there was little 
evidence of a reduction in esophageal cancer-specific mortality with statin use after 
diagnosis. 
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1. Introduction 
In the UK each year over 8,000 people are diagnosed with esophageal cancer.(1) The 
prognosis is poor (5 year survival rates are 8%)(2), and so research into new treatment 
strategies are warranted. Although mainly used to treat hypercholesterolaemia,(3) there is 
increasing evidence from both cell lines and animal models that statins have antitumor 
properties.(4) Preclinical studies have shown, by inhibiting a rate-limiting enzyme (3-
hydroxy-3-methylglutaryl Coenzyme A reductase) in the mevalonate pathway, statins induce 
apoptosis and inhibit angiogenesis.(5,6) Of specific relevance to esophageal cancer, 
Ogunwobi et al showed that statins inhibit proliferation and induce apoptosis in esophageal 
adenocarcinoma cell lines.(7) In humans, recent epidemiological studies have shown 
reductions in esophageal cancer risk in statin users.(8)  
 
Despite these promising findings, there has been little research into the effect of statin use 
after diagnosis on survival from esophageal cancer.  The only previous epidemiological study 
to investigate statin use after diagnosis in esophageal cancer patients concluded that statins 
were associated with large and significant reductions in cancer-specific and all-cause 
mortality.(9)   
 
The association between statin use and esophageal cancer-specific mortality is of importance 
because it will inform the decision to conduct clinical trials of statins as adjuvant cancer 
therapy in esophageal cancer patients.  Therefore, to clarify this association we investigated 
whether statin use after cancer diagnosis was associated with reduced esophageal cancer-
specific and all-cause mortality in a population-based cohort of esophageal cancer patients.   
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2. Materials and methods 
2.1 Data source 
The study utilised linkages between national datasets from Scotland including the Scottish 
Cancer Registry (SMR06), the Prescribing Information System, the General / Acute Inpatient 
and Day Case dataset (SMR01), the Outpatient Attendance dataset (SMR00) and the National 
Records of Scotland Death Records.  The Scottish Cancer Registry captures information on 
all cancers occurring in Scotland including date and site of primary cancer diagnosis, stage, 
grade and treatment data.  The Prescribing Information System (available from January 2009 
to January 2015) holds all medicines dispensed in the community in Scotland.  The General / 
Acute Inpatient and Day Case dataset (available from January 1999 to January 2015) contains 
information on hospital diagnoses and operations and the Outpatient Attendance dataset 
(available from January 1999 to January 2015) contains diagnosis and procedures from new 
and follow up appointments at outpatient clinics.  The National Records of Scotland Death 
Records contain date and cause of death up to January 2015.  Linkages between data sources 
were conducted using the Community Health Index number (a unique number to individuals 
in Scotland).  
 
2.2 Study population 
A cohort of newly diagnosed esophageal cancer patients was identified on the basis of a 
Scottish Cancer Registry recorded primary diagnosis of esophageal cancer (ICD code C15) 
between Jan 2009 and Dec 2012. Cohort members with previous Scottish Cancer Registry 
cancer diagnosis (after January 1999), apart from in situ neoplasms and non-melanoma skin 
cancers, were excluded. 
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Deaths were identified from National Records of Scotland with coverage up to 1st January 
2015 (or from Scottish Cancer Registry death records) with esophageal cancer-specific deaths 
defined as those with underlying cause of death esophageal cancer (C15), gastric cancer 
(C16), or malignant neoplasm of other and ill-defined digestive organs (C26). Patients who 
died in the first 6 months after their esophageal cancer diagnosis were excluded because it 
seemed unlikely that post diagnostic medication use could influence such deaths, therefore 
the follow-up date started 6 months after diagnosis.  The patients were followed from 6 
months after date of esophageal cancer diagnosis to death, the date they left Scotland or 1st 
January 2015. 
 
2.3 Study design 
Exposure data: Statins dispensed in the community (identified from the Prescribing 
Information System) consisted of all medications in the Statins section of the British National 
Formulary (Section 2.12).(10) A quantity of 28 tablets was assumed for the less than 0.1% of 
prescriptions where quantity was assumed incorrect. Daily defined doses (DDD) were 
calculated on the basis of quantity and strength (as defined by the World Health 
Organisation(11)). Statin use was investigated as a time varying covariate.(12) Patients were 
initially considered non-users and then users thereafter for the remainder of follow-up, after a 
lag of 6 months (though this was varied in sensitivity analyses) which was applied to all 
individuals. The use of a lag is recommended(13) and in this study the lag, in effect, removed 
prescriptions in the 6 month period prior to death or end of follow-up, the former of which as 
these may reflect end of life treatment. The study design is described in Figure 1. 
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2.4 Covariates 
Data available from the Scottish Cancer Registry included morphology (from ICD-O codes, 
allowing esophageal adenocarcinoma and squamous cell carcinoma to be identified), 
histological grade and surgery, chemotherapy and radiotherapy in the six months after 
diagnosis.  Comorbidities that contribute to the Charlson index were determined prior to 
diagnosis based upon ICD10 diagnosis codes, as described previously(14) in Scottish hospital 
inpatient (SMR01) and outpatient data (SMR00). A deprivation measure was determined 
using the 2009 Scottish Index of Multiple Deprivation based upon postcode of 
residence.(14,15) 
 
2.5 Statistical analysis 
In the main analysis, time-dependent Cox regression models were used to calculate hazard 
ratios (HRs) for esophageal cancer-specific death and 95% confidence intervals (95% CIs) 
for statin users compared with non-users using a time varying covariate, as described 
previously. Adjusted analyses were conducted including the following potential confounders: 
sex, age, year of diagnosis, deprivation (in fifths), surgery (within 6 months), radiotherapy 
(within 6 months), chemotherapy (within 6 months), comorbidities (prior to diagnosis, 
including acute myocardial infarction, congestive heart failure, peripheral vascular disease, 
cerebral vascular accident, pulmonary disease, peptic ulcer, liver disease, diabetes, renal 
disease) and aspirin usage (as time varying covariate). A dose-response analysis was 
conducted with individuals considered non-users prior to 6 months after first use, a short term 
user between 6 months after first use and 6 months after the 12th prescription and a longer 
term user after this time. Analyses were repeated for all-cause mortality. Log-log plots were 
produced to check the proportional hazard assumptions. The main analysis was repeated 
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comparing simvastatin users to simvastatin non-users (and a separate analysis was conducted 
comparing simvastatin users to statin non-users but gave similar results, not shown). 
 
Subgroup analyses were conducted by gender and histological subtype (esophageal 
adenocarcinoma and squamous cell carcinoma). A separate analysis was conducted stratified 
by statin use in the year prior to diagnosis. A sensitivity analysis was conducted additionally 
adjusting for statin use in the year prior to diagnosis and additionally adjusting for grade. A 
sensitivity analysis was conducted including gastric cancers of the cardia (C16.0) among the 
esophageal cancers. A sensitivity analysis was conducted varying the duration of the lag. 
Specifically, a time varying covariate analysis was conducted using no lag (following patients 
from esophageal cancer diagnosis and not excluding any deaths after cancer diagnosis), a 3 
month lag (following patients from 3 months after esophageal cancer diagnosis and excluding 
deaths prior to 3 months after cancer diagnosis because such patients, by definition could not 
be medication users) and a 12 month lag. Figure 1 illustrates how statin user and non-user 
time was accumulated in the main analysis with a 6 month lag and in the unlagged analysis. 
A simplified analysis was conducted using Cox regression to compare statin users to statin 
non-users in the 6 months after esophageal cancer diagnosis in individuals living more than 6 
months after diagnosis; this controls immortal time bias(16) without requiring time varying 
covariates.  
 
Finally, an analysis was conducted comparing statin users to statin non-users in the year 
before diagnosis (excluding patients diagnosed in 2009 for whom a full year of prescription 
records prior to diagnosis may not be available), not excluding deaths after diagnosis.  An 
adjusted analysis was first conducted omitting cancer treatment from adjustments for 
potential confounders to avoid over-adjustment(17,18) as these could be on the causal 
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pathway for esophageal cancer-specific mortality, but subsequently, a fully adjusted analysis 
was conducted including these variables.  
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3.0 Results 
3.1 Patient cohort 
There were 3,463 esophageal cancer patients diagnosed 2009 to 2012.  Overall, 414 were 
excluded because of a previous cancer diagnosis, and 17 were removed because they died on 
the date of their cancer diagnosis, therefore 3,032 were eligible for analysis.  The main 
analysis of post diagnosis statin use contained 1,921 esophageal cancer patients (because 
1,128 esophageal cancer patients were excluded because they died within 6 months) in whom 
there was a mean of 2 years of follow-up (min=0.5 and maximum=6 years) and there were 
1,502 deaths due to any cause, 1,373 of which were due to esophageal cancer. 
 
Patient characteristics by statin use are shown in Table 1. Statin users were more likely to be 
male, older and diagnosed more recently. A greater proportion of statin users compared with 
non-users had esophageal adenocarcinoma (60% versus 55%, respectively) whilst a slightly 
smaller proportion had poorly differentiated tumours (44% versus 47%, respectively).  Statin 
users were more likely to have radiotherapy and less likely to have surgery or chemotherapy 
compared with non-users.  Statin users were more likely to have comorbidities (particularly 
for cerebrovascular disease, diabetes, stroke and myocardial infarction) and use low dose 
aspirin. 
 
3.2 Association between statin use after diagnosis and survival 
Table 2 shows the main findings. There was little evidence of a reduction in esophageal 
cancer-specific mortality in statin users after diagnosis (adjusted HR=0.93, 95% CI, 0.81, 
1.07, respectively).  There was also little evidence of a dose-response association when 
exposure was investigated by number of prescriptions.  There was also no association when 
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simvastatin was investigated (adjusted HR=1.02, 95% CI 0.89, 1.17).  Similar associations 
were observed for all-cause mortality. 
 
3.3 Subgroup and sensitivity analyses 
Table 3 shows subgroup and sensitivity analyses.  The main findings were similar when 
including cancers of the cardia (C16.0) and additionally adjusting for grade. There was little 
evidence of an association after adjusting for statin use before diagnosis (HR=0.86 95% CI 
0.68, 1.08) or when restricting to statin users in the year prior to diagnosis (HR=0.84 95% CI 
0.64, 1.10) or statin non-users in the year prior to diagnosis (HR=0.69 95% CI 0.35, 1.37). 
Subgroup analyses did not reveal marked differences in the association between statin use 
and esophageal cancer-specific mortality by gender or histologic subtypes (in squamous cell 
carcinoma and esophageal adenocarcinoma the associations were adjusted HR=0.94, 95% CI 
0.73, 1.21 and adjusted HR=0.90, 95% CI 0.75, 1.08, respectively). In a simplified analysis 
comparing statin users in the first 6 months versus non-users (restricted to individuals living 6 
months), the association was similar (adjusted HR=0.90, 95% CI 0.79, 1.03). Associations 
between statins and esophageal cancer-specific mortality were apparent when no lag 
(adjusted HR=0.68 95% CI 0.61, 0.76) or a 3 month lag was used (adjusted HR=0.80 95% CI 
0.70, 0.90) but when longer lags of 6 months (as in the main analysis) or 12 months were 
used the associations were attenuated.  
 
3.4 Association between statin use before diagnosis and survival 
Overall, statin users before diagnosis had a 12% reduction in the rate of esophageal cancer-
specific mortality (fully adjusted HR=0.88, 95% CI 0.79, 0.99) compared with statin non-
users following adjustment for confounders, Table 4. Comparable associations were observed 
for all-cause mortality.   
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4.0 Discussion 
In this population-based cohort, there was little evidence of an association between statin use 
after diagnosis of esophageal cancer and esophageal cancer-specific mortality.  There was 
however a weak association between statin use in the year prior to diagnosis and esophageal 
cancer-specific mortality. 
 
The only previous study(9) to investigate statin use after diagnosis and esophageal cancer-
specific mortality used Clinical Practice Research Datalink data from England (based upon 
GP prescribing data and linked cancer registry data and national mortality data).  This study 
concluded that statins were associated with large and significant reductions in esophageal 
cancer specific mortality.  This conclusion was based upon an unlagged analysis in which 
statin use was associated with marked reductions in esophageal cancer-specific mortality 
(adjusted HR=0.62 95% CI 0.44, 0.86) and this association was similar when the authors 
used a 3 month lag (adjusted HR=0.66, 95% CI 0.41, 1.07, respectively).  We observed a 
similar association in unlagged analysis (adjusted HR=0.68 95% CI 0.61, 0.76), but in 
contrast to their study, this was markedly attenuated when using a 3 month lag (adjusted 
HR=0.80 95% CI 0.70, 0.90) and in our main analysis (using a 6 month lag) there was no 
association (adjusted HR=0.93 95% CI 0.81, 1.07).  The use of a lag is recommended to 
reduce reverse causality(13) which could arise if esophageal cancer patients were less likely 
to start statins when they were obviously close to death.  Observational studies in colorectal 
cancer patients have shown marked reductions in statin prescribing in the six months prior to 
death and stated that inclusion of an exposure lag is vital to account for reverse causation.(19) 
The use of a longer lag explains the difference in conclusion between our studies but the 
reason for the difference in the magnitude of the association when using a 3 month lag 
remains unclear.  
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Our findings of an approximate 10% reduction in cancer-specific and all-cause mortality in 
esophageal cancer patients who use statins before diagnosis is consistent with a nationwide 
Danish study which observed a reduction in cancer-specific mortality of around 20% with 
statin use before diagnosis (adjusted HR = 0.81, 95% CI 0.69, 0.95)(17,18) and the 
previously mentioned English study which observed around a 10% reduction in cancer-
specific and all-cause mortality (adjusted HR=0.91, 95% CI 0.71, 1.16 and adjusted 
HR=0.86, 95% CI 0.55, 1.20, respectively).  The cause of this reduction is unknown, and may 
not be causal, but could reflect the anticancer properties of statins on the developing 
esophageal cancer, seen in preclinical studies, which have shown that statins inhibit 
proliferation, and reduce apoptosis in esophageal adenocarcinoma cell lines.(7) The clinical 
utility of this finding is unclear as it is difficult to intervene prior to esophageal cancer 
diagnosis. Medication use prior to cancer diagnosis may be subject to a healthy user effect, 
whereby those with lesser disease experiencing less severe symptoms may be more likely to 
keep using the medications, compared with patients with more advanced disease 
discontinuing the drug.(20) 
 
Our study has many strengths.  It is the largest cohort to investigate statin use after diagnosis 
and esophageal cancer-specific mortality in esophageal cancer patients.  Despite this, we 
cannot rule out a weak protective effect of statins after diagnosis that we could not detect as 
statistically significant due to lack of power.  The study utilised high quality data sources 
from the Scottish Cancer Registry (allowing a population based cancer cohort to be 
identified), the Prescribing Information System (providing detailed information on the timing 
of medication use allowing temporal associations to be investigation) and the National 
Records of Scotland Death Records (allowing deaths to be captured comprehensively). Our 
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main analysis was conducted using a lag of 6 months, although a lag is recommended,(13) a 
weakness of this approach is that it will by necessity exclude patients who lived less than 6 
months after esophageal cancer diagnosis, therefore restricting the generalizability of results. 
Misclassification of statin use by over the-counter use is likely to be limited as only low dose 
10mg simvastatin is available in Scotland and this accounts for a very small proportion of 
statin use; a UK study recently estimated less than 1% of the population obtain statins the 
over the counter.(21) Similarly, there is the possibility of over-the-counter use of aspirin, 
which was included as a covariate, but previous studies suggest in this age group 70 to 95% 
of use will be captured by prescriptions.(22,23) However, misclassification of statin/aspirin 
use by non-compliance is possible.  As with all observational studies there is the possibility 
of residual confounding, in this instance potential confounders include stage, smoking, 
alcohol and exercise.       
 
In conclusion, in this population based cohort study of esophageal cancer patients, we found 
little evidence of an association between statin therapy after diagnosis and improved survival. 
 
 
Acknowledgements:  The authors would like to thank the research coordinators (Lizzie 
Nicholson and David Bailey) and NHS National Services Scotland for facilitating access and 
analysis of the Scottish cohort.  
 
Ethical approval: The study was approved by the Privacy Advisory Committee of the 
National Health Service (NHS) National Services Scotland (NSS). 
  
	 15
References 
 
1.  Office for National Statistics. Report: Cancer Incidence and Mortality in the United 
Kingdom, 2008-10 [Internet]. London, UK; 2012. Available from: 
http://www.ons.gov.uk/ons/rel/cancer-unit/cancer-incidence-and-mortality/2008-
2010/stb-cancer-incidence-and-mortality-in-the-united-kindom--2008-2010.html 
2.  Mitry E, Rachet B, Quinn MJ  et al. Survival from cancer of the oesophagus in 
England and Wales up to 2001. Br J Cancer. 2008;99(Suppl 1):S11–3.  
3.  Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005 
Jan;45:89–118.  
4.  Demierre M-F, Higgins PDR, Gruber SB, et al. Statins and cancer prevention. Nat Rev 
Cancer. 2005 Dec;5(12):930–42.  
5.  Chan KKW, Oza AM, Siu LL. The Statins as Anticancer Agents. Clin Cancer Res. 
2003;9(1):10–9.  
6.  Gauthaman K, Fong C-Y, Bongso A. Statins, stem cells, and cancer. J Cell Biochem. 
2009;106(6):975–83.  
7.  Ogunwobi OO, Beales ILP. Statins inhibit proliferation and induce apoptosis in 
Barrett’s esophageal adenocarcinoma cells. Am J Gastroenterol. 2008;103(4):825–37.  
8.  Beales ILP, Hensley A, Loke Y. Reduced esophageal cancer incidence in statin users, 
particularly with cyclo-oxygenase inhibition. World J Gastrointest Pharmacol Ther. 
2013;4(3):69–79.  
9.  Alexandre L, Clark AB, Bhutta HY, et al. Association Between Statin Use After 
Diagnosis of Esophageal Cancer and Survival: a Population-based Cohort Study. 
Gastroenterology. 2016;150(4):854–65.  
10.  British Medical Association and the Royal Pharmaceutical Society of Great Britain. 
	 16
British National Formulary [Internet]. 68th ed. 2014. Available from: 
http://www.bnf.org/bnf/index.htm 
11.  World Health Organisation. World Health Organisation Collaborating Centre for Drug 
Statistics Methodology. 2016.  
12.  Lévesque LE, Hanley JA, Kezouh A, et al. Problem of immortal time bias in cohort 
studies: example using statins for preventing progression of diabetes. BMJ. 
2010;340:b5087.  
13.  Chubak J, Boudreau DM, Wirtz HS, et al. Threats to validity of nonrandomized studies 
of postdiagnosis exposures on cancer recurrence and survival. J Natl Cancer Inst. 
2013;105(19):1456–62.  
14.  Sundararajan V, Henderson T, Perry C, et al. New ICD-10 version of the Charlson 
comorbidity index predicted in-hospital mortality. J Clin Epidemiol. 
2004;57(12):1288–94.  
15.  The Scottish Government. Scottish Index of Multiple Deprivation 2009: General 
Report. Edinburgh, UK: A Scottish Government National Statistics Publication. 2009.  
16.  Zhou Z, Rahme E, Abrahamowicz M, et al. Survival bias associated with time-to-
treatment initiation in drug effectiveness evaluation: a comparison of methods. Am J 
Epidemiol. 2005;162(10):1016–23.  
17.  Weinberg CR. Toward a clearer definition of confounding. Am J Epidemiol. 
1993;137(1):1–8.  
18.  Schisterman EF, Cole SR, Platt RW. Overadjustment bias and unnecessary adjustment 
in epidemiologic studies. Epidemiology. 2009;20(4):488–95.  
19.  Smith A, Murphy L, Bennett K, et al. Patterns of statin initiation and continuation in 
patients with breast or colorectal cancer, towards end-of-life. Support Care Cancer 
[Internet]. 2017 Jan 18 [cited 2017 Jan 31]; Available from: 
	 17
http://www.ncbi.nlm.nih.gov/pubmed/28101676 
20.  Shrank WH, Patrick AR, Brookhart MA. Healthy user and related biases in 
observational studies of preventive interventions: a primer for physicians. J Gen Intern 
Med. 2011;26(5):546–50.  
21.  Mainous AG, Baker R, Everett CJ, et al. Impact of a policy allowing for over-the-
counter statins. Qual Prim Care. 2010 Jan;18(5):301–6.  
22.  Bedson J, Whitehurst T, Lewis M, et al. Factors affecting over-the-counter use of 
aspirin in the secondary prophylaxis of cardiovascular disease. Br J Gen Pract. 2001 
Dec;51(473):1001–3.  
23.  Yang Y-X, Hennessy S, Propert K, et al. Chronic statin therapy and the risk of 
colorectal cancer. Pharmacoepidemiol Drug Saf. 2008;17(9):869–76.  
	 18
Table 1.  Statin Use Before and After Esophageal Cancer Diagnosis, Scotland, 2009-2012. 
 Statin use after diagnosisa  Statin use before diagnosisb 
 Statin  No Statin  Statin  No Statin 
 n % n % n % n % 
Year of diagnosis        
  2009 163 25.3 312 24.5     
  2010 150 23.3 329 25.8 298 32.7 493 35.5 
  2011 156 24.2 303 23.7 295 32.3 431 31 
  2012 176 27.3 332 26 319 35 466 33.5 
         
Male 468 72.6 803 62.9 606 66.4 876 63 
         
Age at diagnosis         
  <60 68 10.5 326 25.5 69 7.6 307 22.1 
  60-69 205 31.8 396 31 237 26 383 27.6 
  70-79 248 38.4 350 27.4 345 37.8 384 27.6 
  80-89 114 17.7 170 13.3 238 26.1 243 17.5 
  ≥ 90 10 1.6 34 2.7 23 2.5 73 5.3 
         
         
Morphology         
 Squamous cell 192 29.8 451 35.3 283 31 484 34.8 
 Adenocarcinoma 389 60.3 699 54.8 500 54.8 721 51.9 
 Missing 64 9.9 126 9.9 129 14.1 185 13.3 
         
Grade         
  1 8 1.2 29 2.3 16 1.8 22 1.6 
  2 219 34 412 32.3 289 31.7 405 29.1 
  3 281 43.6 602 47.2 400 43.9 686 49.4 
  Missing 137 21.2 233 18.3 207 22.7 277 19.9 
         
Deprivation (fifth)        
  1 (most deprived) 165 25.6 277 21.7 213 23.4 307 22.1 
  2 141 21.9 250 19.6 216 23.7 307 22.1 
  3 131 20.3 271 21.2 187 20.5 290 20.9 
  4 117 18.1 251 19.7 185 20.3 263 18.9 
  5 (least deprived) 91 14.1 227 17.8 111 12.2 223 16 
         
Treatment (within 6 months)       
  Surgery 110 17.1 246 19.3 89 9.8 192 13.8 
  Radiotherapy 229 35.5 383 30 245 26.9 318 22.9 
  Chemotherapy 352 54.6 787 61.7 326 35.7 620 44.6 
         
Comorbidity prior to diagnosis      
  Acute myocardial infarction 80 12.4 22 1.7 130 14.3 30 2.2 
  Congestive heart failure 49 7.6 36 2.8 84 9.2 42 3 
  Peripheral vascular  disease 46 7.1 21 1.6 86 9.4 27 1.9 
  Cerebral vascular accident 70 10.9 29 2.3 118 12.9 48 3.5 
  Pulmonary disease 89 13.8 100 7.8 144 15.8 140 10.1 
  Peptic ulcer  23 3.6 56 4.4 32 3.5 67 4.8 
  Diabetes 97 15 36 2.8 148 16.2 36 2.6 
  Renal disease 33 5.1 19 1.5 53 5.8 28 2 
         
Medication usec        
  Aspirin  352 54.6 134 10.5 539 59.1 171 12.3 
aStatin use in the 6 months after diagnosis restricted to esophageal cancer patients living 6 months after diagnosis. 
bStatin use in the year prior to diagnosis. 
cRefers to aspirin use in the 6 months after diagnosis in the first four columns and aspirin use in the year prior to 
diagnosis in the next four columns. 
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Table 2. Association Between Statin Use After Diagnosis and Cancer-specific and All-cause Mortality in Patients With Esophageal Cancer, 
Scotland, 2009-2012.   
 Mortality Patients 
Person 
years 
Unadjusted HR 
(95% CI) 
P Adjusteda HR 
(95%CI) 
P 
Cancer-specific mortality 
 
Statin non-user 948 1270 1677 1.00 (ref. cat.)  1.00 (ref. cat.)  
Statin user 425 651 874 0.97 (0.86,1.09) 0.62 0.93 (0.81,1.07) 0.29 
        
1-12 prescriptions 387 496 677 0.97 (0.86,1.09) 0.94 0.92 (0.80,1.06) 0.27 
≥ 12 prescriptions 38 155 198 1.01 (0.71,1.45) 0.58 0.97 (0.67,1.39) 0.86 
        
Simvastatin non-user 1081 1479 1960 1.00 (ref. cat.)  1.00 (ref. cat.)  
Simvastatin user 292 442 592 1.03 (0.90,1.17) 0.70 1.02 (0.89,1.17) 0.78 
        
All-cause mortality 
All-cause mortality        
Statin non-user 1017 1270 1677 1.00 (ref. cat.)  1.00 (ref. cat.)  
Statin user 485 651 874 1.02 (0.92,1.14) 0.70 0.94 (0.82,1.07) 0.36 
        
1-12 prescriptions 426 496 677 1.00 (0.89,1.12) 0.13 0.92 (0.80,1.05) 0.22 
≥ 12 prescriptions 59 155 198 1.25 (0.94,1.68) 0.98 1.15 (0.85,1.56) 0.35 
        
Simvastatin non-user 1174 1479 1960 1.00 (ref. cat.)  1.00 (ref. cat.)  
Simvastatin user 328 442 592 1.05 (0.92,1.18) 0.48 1.01 (0.88,1.15) 0.91 
aTime varying covariate analysis (with 6 month lag, removing deaths in the first 6 months) with adjusted estimates based upon  model which contains sex, age, year of 
diagnosis, deprivation, cancer treatment within 6 months (radiotherapy, chemotherapy, surgery), comorbidities (prior to diagnosis, including acute myocardial infarction, 
congestive heart disease, peripheral vascular disease, cerebral vascular accident, pulmonary disease, peptic ulcer, liver disease, diabetes, renal disease) and aspirin use (as 
time varying covariate). 
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Table 3. Sensitivity Analysis of Association Between Statin Use and Cancer-specific and All-cause Mortality in Patients With Esophageal 
Cancer, Scotland, 2009-2012. 
 Medication user  Medication non-user Unadjusted HR 
(95% CI) P 
Adjusted HR 
(95%CI) P   
Cancer-specific
mortality Patients 
Person 
years 
Cancer-specific 
mortality Patients 
Person 
years 
Subgroup analyses:  Statin users versus non-usersa           
   Male 316 477 636 596 794 1046 0.97 (0.84,1.11) 0.66 0.94 (0.79,1.11) 0.466     Female 109 174 238 352 476 631 0.96 (0.77,1.19) 0.72 0.89 (0.69,1.14) 0.346 
   ESCC 126 192 246 340 451 571 0.99 (0.80,1.21) 0.89 0.94 (0.73,1.21) 0.629     EACC 255 395 538 513 693 954 0.97 (0.84,1.14) 0.74 0.90 (0.75,1.08) 0.267 
   In statin users in year priore 306 456 540 105 122 128 0.84 (0.65,1.08) 0.179 0.84 (0.64,1.10) 0.214  
   In statin non-users in year priore 9 35 50 596 833 1086 0.52 (0.27,1.02) 0.057 0.69 (0.35,1.37) 0.293  
            
Statin user versus non-usera           
 Adjusting for statin use in the year 
prior to diagnosisf 315 491 589 701 955 1214 1.01 (0.88,1.16) 0.884 0.86 (0.68,1.08) 0.184  
 Including cardia cancerb  531 824 1139 1194 1598 2157 0.94 (0.85,1.04) 0.24 0.89 (0.79,1.01) 0.072  
 Grade available (and adjusted for) 335 514 682 782 1037 1381 0.97 (0.85, 1.10) 0.60 0.90 (0.77, 1.06) 0.20  
            
Statin user versus non-user           
  Simplified analysis 6 monthsc 450 645 862 923 1276 1690 0.94 (0.84,1.05) 0.27 0.90 (0.79,1.03) 0.13  
            
Statin user versus non-userd            
  No lag 610 860 1255 1775 2172 2511 0.74 (0.67,0.81) <0.001 0.68 (0.61,0.76) <0.001  
  3 month lag 526 765 1049 1268 1618 2037 0.88 (0.79,0.97) 0.01 0.80 (0.70,0.90) <0.001  
  12 months lag 216 418 614 481 785 1171 0.94 (0.80,1.10) 0.44 0.84 (0.69,1.02) 0.077  
aTime varying covariate analysis (with 6 month lag, removing deaths in the first 6 months) in with adjusted estimates based upon  model which contains sex, age, year of 
diagnosis, deprivation, cancer treatment within 6 months (radiotherapy, chemotherapy, surgery), comorbidities (prior to diagnosis, including acute myocardial infarction, 
congestive heart disease, peripheral vascular disease, cerebral vascular accident, pulmonary disease, peptic ulcer, liver disease, diabetes, renal disease) and aspirin use (as 
time varying covariate). 
bIncludes cancer of the cardia (C16.0) in esophageal cancer definition. 
cSimplified analysis, comparing statin users to statin non-users in the 6 months after diagnosis in individuals living more than 6 months after cancer diagnosis, adjusted for all 
confounders in a but other medication use also restricted to first 6 months after diagnosis. 
dTime varying covariate analysis (using model in a) varying the duration of lag from no lag (not removing any deaths after diagnosis), to a 3 month lag (removing deaths in 
the first 3 months after diagnosis), a 6 month lag (removing deaths in the first 6 months after diagnosis) or a 12 month lag (removing deaths within the first 12 months after 
diagnosis).   
eStatin users versus non-users after diagnosis using model in a, stratified by statin use in the year prior to diagnosis, restricted to esophageal cancer cases diagnosed 2010 to 
2012.  
fStatin users versus non-users after diagnosis using model in a, adjusting for statin use in the year prior to diagnosis, restricted to esophageal cancer cases diagnosed 2010 to 
2012.  
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Table 4. Association Between Statin Use Before Diagnosis and Cancer-specific and All-cause Mortality in Patients With Esophageal Cancer, 
Scotland, 2009-2012.  
 Mortality Patients 
Person 
years 
Unadjusted HR 
(95% CI) 
P Adjusted1 HR 
(95%CI) 
P Fully adjusted2HR 
(95%CI) 
P 
Cancer-specific mortality 
          
Statin non-user 1085 1390 1684 1.00 (ref. cat.)  1.00 (ref. cat.)  1.00 (ref. cat.)  
Statin user 713 912 1036 1.03 (0.91, 1.13) 0.58 0.85 (0.76, 0.96) 0.01 0.88 (0.79, 0.99) 0.03 
          
Simvastatin non-user 1283 1658 2016 1.00 (ref. cat.)  1.00 (ref. cat.)  1.00 (ref. cat.)  
Simvastatin user 515 644 704 1.11 (1.00, 1.23) 0.05 0.98 (0.87, 1.09) 0.69 0.98 (0.88, 1.10) 0.72 
All-cause mortality 
          
Statin non-user 1169 1390 1684 1.00 (ref. cat.)  1.00 (ref. cat.)  1.00 (ref. cat.)  
Statin user 789 912 1036 1.06 (0.97, 1.16) 0.23 0.86 (0.77, 0.96) 0.01 0.89 (0.80, 0.99) 0.04 
          
Simvastatin non-user 1393 1658 2016 1.00 (ref. cat.)  1.00 (ref. cat.)  1.00 (ref. cat.)  
Simvastatin user 565 644 704 1.12 (1.01,1.23) 0.02 0.97 (0.87,1.08) 0.55 0.97 (0.87,1.08) 0.59 
1Model contains sex, age, year of diagnosis, deprivation, comorbidities (prior to diagnosis, including acute myocardial infarction, congestive heart disease, peripheral vascular 
disease, cerebral vascular accident, pulmonary disease, peptic ulcer, liver disease, diabetes, renal disease) and aspirin and statin use (in year prior to diagnosis). 
2Model contains all variables in 1 along with cancer treatment within 6 months (radiotherapy, chemotherapy, surgery). 
 
 
